We are breaking the current pattern of metabolic disease management and simplifying it.
Our therapeutic approaches target key metabolic control organs – like the duodenum and the pancreas – in which dysfunction is a root cause of serious conditions like obesity and type 2 diabetes. By designing our therapies to target root causes, we aim to prevent, reverse, and even put an end to these diseases, once and for all.
Revita® and Rejuva® — disease modifying therapies addressing obesity and type 2 diabetes.
Revita
An outpatient endoscopic procedure designed to resurface the lining of the duodenum—targeting a root cause of obesity and type 2 diabetes.
Rejuva
A one-time gene therapy platform designed to enable the long-term remission of obesity and type 2 diabetes by targeting pancreatic islet cells.
Our mission: advance the collective knowledge of metabolic disease.
We are driven to dig deeper into the root causes—and potential therapeutic approaches—for serious metabolic diseases like obesity and type 2 diabetes. We aim to break the pattern of a lifelong course of drugs, and we’re working to develop approaches that can stop or reverse these diseases, once and for all.
Revita® is for investigational use only in the US under Federal law. We hereby disclaim any warranties or guarantees regarding the efficacy or safety of Revita®. While we strive for quality and reliability, individual results may vary. Users are encouraged to consult with healthcare professionals and assess personal suitability before using the device.
Rejuva® is in early development and not approved by any regulatory body for investigational or commercial use.